For more than a decade human papillomavirus (HPV) vaccine have been implemented in
most high-income countries, and more recently also in several low-and middle-income …

Human papilloma virus (HPV) vaccination has been implemented in several countries for
about the past 7 years, mainly in the adolescent female population, with varying coverage …

Cervical cancer incidence and mortality have decreased in high-income countries, but low-
and middle-income countries continue to bear a significant burden from the disease. Human …

Two licensed vaccines designed to prevent certain human papillomavirus (HPV) infections
are currently available. Their use to prevent cervical cancer has depended on data from …

Given the low rates of Human Papillomavirus (HPV) vaccination initiation and timely series
completion in 11-and 12-year old children, we sought to assess potential opportunities for …

Human papillomavirus vaccines have been in use in populations for nearly 10 years. They
now have an established record of high efficacy, effectiveness and safety in the prevention …

The link between human papillomavirus (HPV) infection and different diseases has been
well-established since more than four decades ago [1, 2]. Moreover, high-risk HPV types …

Prophylactic HPV vaccines hold tremendous potential for reducing cervical and non-cervical
HPV-related disease burden worldwide. To maximize on this potential, policy officials will …

Over a decade has passed since the first human papillomavirus (HPV) vaccine was
introduced. These vaccines have received unequivocal backing from the scientific and …

The availability of prophylactic human papillomavirus (HPV) vaccines has provided powerful
tools for primary prevention of cervical cancer and other HPV-associated diseases. Since …